Acoustic neuroma screening

Jump to: navigation, search

Acoustic neuroma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acoustic neuroma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

MRI

CT

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acoustic neuroma screening On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acoustic neuroma screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acoustic neuroma screening

CDC on Acoustic neuroma screening

Acoustic neuroma screening in the news

Blogs on Acoustic neuroma screening</small>

Directions to Hospitals Treating Acoustic neuroma

Risk calculators and risk factors for Acoustic neuroma screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]

Overview

According to the USPTF, screening for acoustic neuroma is not recommended. Evaluation for NF-2 should be done in individuals with an apparently sporadic vestibular schwannoma occurring at less than 30 years of age, or a spinal tumor or meningioma occurring at less than 20 years of age.[1]

Screening

According to the USPTF, screening for acoustic neuroma is not recommended. Annual hearing screening with BAER (Brain stem auditory evoked response test), with referral to an audiologist for amplification, or speech therapy is recommended in patients with NF-2. Evaluation for NF-2 should be done in individuals with an apparently sporadic vestibular schwannoma occurring at less than 30 years of age, or a spinal tumor or meningioma occurring at less than 20 years of age.[1]

References

  1. 1.0 1.1 Evans DG, Ramsden RT, Gokhale C, Bowers N, Huson SM, Wallace A (2007). "Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?". Clin Genet. 71 (4): 354–8. PMID 17470137. doi:10.1111/j.1399-0004.2007.00778.x. 

Linked-in.jpg